Geron Corporation (GERN)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Geron Nears FDA Decision on Cancer Drug Imetelstat
# 🔎 What This Document Is This is Geron Corporation's **Annual Report to Security Holders**. Think of it as the company's yearly "check-in" letter to its investors, going beyond the basic SEC forms to tell a more complete story of their business, progress, and plans. It’s designed to be a comprehe
Geron Sets Annual Meeting to Vote on Directors and Equity Plan
# 🧾 What This Document Is This is a **proxy statement** (DEF 14A), a formal document sent to shareholders before a company's annual meeting. Its purpose is to give you the information you need to vote on important company matters. Think of it as an agenda and a detailed guidebook for the meeting.
SEC filings
All filings →Insider trades
All insider trades →Geron Corporation has no reported insider trades in the last 90 days.